Eversheds Sutherland advises Edwards Lifesciences on its US$4.2bn sale of Critical Care
September 06, 2024
Eversheds Sutherland advises Edwards Lifesciences on its US$4.2bn sale of Critical CareSeptember 06, 2024 Eversheds Sutherland has advised Edwards Lifesciences on the US$4.2bn sale of its Critical Care product group to Becton, Dickinson and Company (BD). Edwards Lifesciences is a global leader in patient-focused medical innovations for structural heart disease. The Critical Care product group is an industry leader in advanced patient monitoring with advanced AI algorithms serving millions of patients globally. Key contacts
Lee Harris Partner United Kingdom Antony Walsh Partner United Kingdom Barri Mendelsohn Partner United Kingdom Rachel Cooper Partner United Kingdom Edward M. Tompkin-Haag Partner United Kingdom Kelly Holmes Partner United Kingdom Philip Crosbie Partner United Kingdom Christopher Murray Partner United Kingdom Latest InsightsLatest Events
legal updates August 20, 2026 Eversheds Sutherland advises on major renewable energy investment in Syria legal updates August 13, 2026 Hong Kong: Actions to take under critical infrastructure cybersecurity regi... legal updates August 11, 2026 Global Sustainability & ESG Insights - July 2026 legal updates August 11, 2026 EU Packaging and Packaging Waste Regulation virtual UAE - Employment law in the Dubai International Financial Centre September 10, 2026 9.30am - 1.30pm (GMT) Virtual in-person September 10, 2026 9.30am - 1.00pm (BST) London, United Kingdom in-person September 17, 2026 9.30am - 4.30pm (GMT) London, United Kingdom in-person September 23, 2026 Washington DC, United States |